Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data
Frank DeStefano, Dina Pfeifer, Hanna Nohynek
Volume 86, Number 5, May 2008, 373-380
Table 4. Reactogenicity of PCV9 and PCV11 according to age at dose administration: schedules were compatible with the WHO Expanded Programme on Immunization
| Reactogenicity | Obaro et al. |
Capeding et al. |
|||
|---|---|---|---|---|---|
| Vaccine (n) | PCV9 (104) | PCV11 (50) | |||
| Comparison (n) | IPV (102) | DTwPHib (opposite thigh) | |||
| Redness(> 2 cm) | 2 | – | 6 | 0 | |
| 3 | – | 10 | 0 | ||
| 4 | – | 14 | 0 | ||
| Swellingb | 2 | ns | 6 | 7.8 | |
| 3 | 6c | 10 | 4.1 | ||
| 4 | 8c | 14 | 0 | ||
| Tenderness | 2 | ns | 6 | – | |
| 3 | 15c | 10 | – | ||
| 4 | 18c | 14 | – | ||
| Fever(> 38.7 ºC) | 2 | – | 6 | 8.0 | |
| 3 | – | 10 | 12.2 | ||
| 4 | – | 14 | 8.5 | ||
DTwPHib, diphtheria, tetanus, pertussis (cellular antigens), and Haemophilus influenzae type b; IPV, inactivated polio vaccine; ns, not significant; PCV9, nonavalent pneumococcal polysaccharide-protein conjugate vaccine.a PCV11 site for local reactions.b Obaro: > 5 mm; Capeding: > 2 cm.c Significantly higher (P < 0.05) with PCV7 than IPV.